|
Compound was tested for the inhibition of HeLa DNA polymerase
|
None
|
17.0
%
|
|
|
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
|
Homo sapiens
|
17.0
ug.mL-1
|
|
|
Inhibition of DNA polymerase
|
None
|
60.0
%
|
|
|
Inhibition of DNA polymerase
|
None
|
22.0
%
|
|
|
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures
|
Anas sp.
|
1.5
ug.mL-1
|
|
|
Effective concentration required against HCMV AD169 for antiviral activity
|
Human herpesvirus 5
|
0.77
ug.mL-1
|
|
|
Effective concentration required against HCMV strain for antiviral activity
|
Human herpesvirus 5
|
0.62
ug.mL-1
|
|
Effective concentration required against HCMV strain for antiviral activity
|
Human herpesvirus 5
|
7.5
ug.mL-1
|
|
Effective concentration required against HCMV strain for antiviral activity
|
Human herpesvirus 5
|
10.8
ug.mL-1
|
|
|
Tested for antiviral activity against HCMV (AD169)
|
Human herpesvirus 5
|
0.6
ug.mL-1
|
|
|
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls.
|
Duck hepatitis B virus
|
1.5
ug.mL-1
|
|
|
Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines
|
None
|
1.2
nM
|
|
|
Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines
|
None
|
1.2
nM
|
|
|
Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line
|
epstein barr virus
|
50.0
nM
|
|
|
Compound was tested for Anti-HCMV activity against F2002 cell line(exp 1)
|
Homo sapiens
|
0.1
ug.mL-1
|
|
|
Compound was tested for Anti-HCMV activity against F2002 cell line(exp 2)
|
Homo sapiens
|
0.2
ug.mL-1
|
|
|
Inhibitory activity against human cytomegalo virus (WFI strain) in a plaque reduction assay in flow 2002 human fibroblast cells
|
Homo sapiens
|
0.1
ug.mL-1
|
|
|
Compound was tested for antiviral activity against HCMV in DNA hybridization assay
|
Human herpesvirus 5
|
880.0
nM
|
|
|
Antiviral activity against human cytomegalovirus
|
Human herpesvirus 5
|
230.0
nM
|
|
|
Compound was evaluated for the antiviral activity against HCMV
|
Human herpesvirus 5
|
0.74
ug.mL-1
|
|
|
Tested for antiviral activity against HCMV in AD169 cell line
|
Human herpesvirus 5
|
0.98
ug.mL-1
|
|
|
Tested for antiviral activity against HCMV in Davis cell line
|
Human herpesvirus 5
|
4.07
ug.mL-1
|
|
|
Antiviral activity was determined against Human cytomegalovirus (HCMV) strain AD-169 using CPE inhibition assay
|
Human herpesvirus 5
|
1.09
ug.mL-1
|
|
|
Antiviral activity was determined against Human cytomegalovirus (HCMV) strain Davis using CPE inhibition assay
|
Human herpesvirus 5
|
0.61
ug.mL-1
|
|
|
In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.
|
Human herpesvirus 5 strain AD169
|
630.0
nM
|
|
|
Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay).
|
Homo sapiens
|
4.4
ug.mL-1
|
|
|
Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay).
|
Homo sapiens
|
52.0
ug.mL-1
|
|
|
Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV
|
Homo sapiens
|
600.0
nM
|
|
|
Compound was tested for anti-viral activity against HSV-1(G) in HEL cells
|
Homo sapiens
|
60.0
nM
|
|
|
Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures
|
Homo sapiens
|
900.0
nM
|
|
|
Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures
|
Homo sapiens
|
800.0
nM
|
|
|
Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells
|
Homo sapiens
|
2.0
ug.mL-1
|
|
|
Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells
|
Homo sapiens
|
1.5
ug.mL-1
|
|
|
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.
|
Homo sapiens
|
0.02
ug.mL-1
|
|
|
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%
|
Homo sapiens
|
0.072
ug.mL-1
|
|
|
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.
|
Homo sapiens
|
2.9
ug.mL-1
|
|
|
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.
|
Homo sapiens
|
6.2
ug.mL-1
|
|
|
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.
|
Homo sapiens
|
0.1
ug.mL-1
|
|
|
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.
|
Homo sapiens
|
0.9
ug.mL-1
|
|
|
Inhibition of human CMV DNA synthesis in CMV-infected HEL cells.
|
None
|
500.0
nM
|
|
|
Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells
|
Homo sapiens
|
1.2
ug.mL-1
|
|
|
Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells
|
Homo sapiens
|
1.3
ug.mL-1
|
|
|
Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells
|
Human herpesvirus 5
|
0.5
ug.mL-1
|
|
|
Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells
|
Cytomegalovirus
|
0.5
ug.mL-1
|
|
|
Tested for antiviral activity against HSV-1 (KOS)
|
Human herpesvirus 1
|
0.001
ug.mL-1
|
|
|
Tested for antiviral activity against HSV-1 (TK-KOS)
|
Human herpesvirus 1
|
0.48
ug.mL-1
|
|
|
Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle
|
Human herpesvirus 1
|
0.019
ug.mL-1
|
|
|
Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
|
Human herpesvirus 1
|
0.019
ug.mL-1
|
|
|
Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
|
Human herpesvirus 1
|
2.4
ug.mL-1
|
|
|
Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle
|
Human herpesvirus 1
|
0.019
ug.mL-1
|
|
|
Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line
|
herpes simplex virus
|
100.0
nM
|
|
|
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%
|
Human herpesvirus 2
|
230.0
nM
|
|
|
Tested for antiviral activity against HSV-2 (G)
|
Human herpesvirus 2
|
0.002
ug.mL-1
|
|
|
Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle
|
hsv-2
|
0.032
ug.mL-1
|
|
|
Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle
|
hsv-2
|
0.019
ug.mL-1
|
|
|
Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle
|
hsv-2
|
0.019
ug.mL-1
|
|
|
Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line
|
herpes simplex virus
|
100.0
nM
|
|
|
Compound was tested for the inhibition of HSV-1 polymerase
|
Human herpesvirus 1
|
60.0
%
|
|
|
Evaluated for DNA polymerase inhibition activity against herpes simplex virus-1 (HSV-1)
|
Human herpesvirus 1
|
55.0
%
|
|
|
Evaluated for DNA polymerase inhibition activity against HeLa cells.
|
herpes simplex virus-2
|
13.0
%
|
|
|
Concentration required to inhibit human cytomegalovirus HCMV-AD169 in antiviralplaque reduction assay
|
Human herpesvirus 5
|
720.0
nM
|
|
|
Concentration of compound required to inhibit 50% of HCMV strain AD-169 induced cytopathic effect
|
Human herpesvirus 5
|
1.9
ug.mL-1
|
|
|
Concentration of compound required to inhibit 50% of HCMV strain Davis induced cytopathic effect
|
Human herpesvirus 5
|
0.8
ug.mL-1
|
|
|
Antiviral activity was tested against human cytomegalovirus AD-169 which reduces virus plaque formation by 50%
|
Human herpesvirus 5
|
0.3
ug.mL-1
|
|
|
Antiviral activity was tested against human cytomegalovirus Davis which reduces virus plaque formation by 50%
|
Human herpesvirus 5
|
0.4
ug.mL-1
|
|
|
Compound was tested in vitro for inhibitory activity against HCMV (Human cytomegalovirus)
|
Human herpesvirus 5
|
0.1
ug.mL-1
|
|
|
The concentration required to reduce virus plaque formation by 50% was measured on AD-169 strains of human cytomegalovirus
|
Human herpesvirus 5
|
1.2
ug.mL-1
|
|
|
The concentration required to reduce virus plaque formation by 50% was measured on Davis strains of human cytomegalovirus
|
Human herpesvirus 5
|
1.9
ug.mL-1
|
|
|
The compound was tested for the cytomegalovirus; Effective concentration required to inhibit 50% virus proliferation
|
Cytomegalovirus
|
0.1
ug.mL-1
|
|
|
Antiviral activity determined against human cytomegalovirus (HCMV) in Hs 68 cell line by plaque reduction assay
|
Human herpesvirus 5
|
0.3
ug.mL-1
|
|
|
Anti-HCMV activity in the human fibroblast Hs 68 cell line
|
Human herpesvirus 5
|
0.3
ug.mL-1
|
|
|
Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells
|
Homo sapiens
|
500.0
nM
|
|
|
Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay).
|
Homo sapiens
|
3.2
ug.mL-1
|
|
|
Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
|
Homo sapiens
|
2.1
ug.mL-1
|
|
|
Tested for antiviral activity against HBV (Hep AD79)
|
Hepatitis B virus
|
45.0
ug.mL-1
|
|
|
In vitro antiviral activity against Human cytomegalovirus (HCMV) was determined
|
Human herpesvirus 5
|
780.0
nM
|
|
|
Compound was evaluated for its cytotoxicity.
|
None
|
10.0
ug.mL-1
|
|
|
Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle
|
Vaccinia virus
|
100.0
ug.mL-1
|
|
|
Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle
|
Vesicular stomatitis virus
|
100.0
ug.mL-1
|
|
|
Effective concentration against AD-169 strain of CMV virus expressed in HEL cells
|
Cytomegalovirus
|
0.37
ug.mL-1
|
|
|
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture
|
Homo sapiens
|
100.0
ug.mL-1
|
|
|
Effective concentration against Davis strain of CMV virus expressed in HEL cells
|
Cytomegalovirus
|
0.37
ug.mL-1
|
|
|
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture
|
Homo sapiens
|
0.003
ug.mL-1
|
|
|
Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture
|
Cytomegalovirus
|
500.0
nM
|
|
|
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture
|
Homo sapiens
|
0.004
ug.mL-1
|
|
|
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture
|
Homo sapiens
|
2.4
ug.mL-1
|
|
|
Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells
|
Human herpesvirus 1
|
60.0
nM
|
|
|
Effective concentration required to reduce plaque formation by Davis strain of CMV virus in Human embryonic lung cells
|
None
|
0.34
ug.mL-1
|
|
|
Effective concentration required to reduce plaque formation by AD-169 strain of CMV virus in Human embryonic lung cells
|
None
|
0.24
ug.mL-1
|
|
|
Effective concentration of the compound to reduce plaque-formation of Cytomegalovirus davis strain in human embryonic lungcell cultures
|
Cytomegalovirus
|
0.34
ug.mL-1
|
|
|
Effective concentration to reduce plaque formation of Cytomegalovirus AD-169 strain in human embryonic lung cell cultures
|
Cytomegalovirus
|
0.24
ug.mL-1
|
|
|
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line
|
Chlorocebus sabaeus
|
1.22
ug.mL-1
|
|
|
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line
|
Chlorocebus sabaeus
|
1.274
ug.mL-1
|
|
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line
|
Homo sapiens
|
1.2
ug.mL-1
|
|
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line
|
Homo sapiens
|
2.7
ug.mL-1
|
|
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line
|
Homo sapiens
|
2.2
ug.mL-1
|
|
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line
|
Homo sapiens
|
7.8
ug.mL-1
|
|
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line
|
Homo sapiens
|
8.7
ug.mL-1
|
|
|
Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
Homo sapiens
|
800.0
nM
|
|
|
Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
Homo sapiens
|
800.0
nM
|
|
|
Antiviral activity against HSV1 KOS in HEL cells
|
Human herpesvirus 1
|
60.0
nM
|
|
|
Antiviral activity against HSV2 G in HEL cells
|
Human herpesvirus 2
|
60.0
nM
|
|
|
Antiviral activity against Cytomegalovirus AD169 in human embryonic lung cells
|
Cytomegalovirus
|
3.2
ug.mL-1
|
|
|
Antiviral activity against Cytomegalovirus Davis in human embryonic lung cells
|
Cytomegalovirus
|
3.2
ug.mL-1
|
|
|
Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay
|
Human herpesvirus 5
|
150.0
nM
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine
|
Homo sapiens
|
41.0
nM
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
|
Homo sapiens
|
33.0
nM
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
|
Homo sapiens
|
18.0
nM
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
|
Homo sapiens
|
110.0
nM
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
|
Homo sapiens
|
81.0
nM
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
|
Homo sapiens
|
50.0
nM
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK
|
Homo sapiens
|
1.9
nM
|
|
|
Antiviral activity against HSV1 KOS in HEL cells
|
Human herpesvirus 1 strain KOS
|
19.0
nM
|
|
|
Antiviral activity against HSV2 in HEL cells
|
Human herpesvirus 2
|
32.0
nM
|
|
|
Antiviral activity against HSV1 KOS in HEL cells
|
Human herpesvirus 1 strain KOS
|
480.0
nM
|
|
|
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 1 strain KOS
|
0.00038
ug.mL-1
|
|
|
Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 1 strain KOS
|
0.91
ug.mL-1
|
|
|
Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 2
|
0.0014
ug.mL-1
|
|
|
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 2
|
0.0096
ug.mL-1
|
|
|
Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 5
|
1.5
ug.mL-1
|
|
|
Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 5
|
1.5
ug.mL-1
|
|
|
Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
0.002
ug.mL-1
|
|
|
Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 2
|
0.007
ug.mL-1
|
|
|
Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
Vaccinia virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1
|
0.7
ug.mL-1
|
|
|
Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1
|
0.02
ug.mL-1
|
|
|
Antiviral activity against HCMV in MRC5 cells by plaque reduction assay
|
Human herpesvirus 5
|
910.0
nM
|
|
|
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
0.00056
ug.mL-1
|
|
|
Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
0.9
ug.mL-1
|
|
|
Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 2
|
0.0014
ug.mL-1
|
|
|
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 2
|
0.0036
ug.mL-1
|
|
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
1.68
ug.mL-1
|
|
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
1.29
ug.mL-1
|
|
|
Cytotoxicity against MCA-TK cells
|
Homo sapiens
|
150.0
nM
|
|
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days
|
Human herpesvirus 5 strain AD169
|
0.51
ug.mL-1
|
|
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days
|
Human herpesvirus 5
|
0.8
ug.mL-1
|
|
|
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
Human herpesvirus 1
|
700.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 5 strain AD169
|
40.0
nM
|
|
|
Antiviral activity against mouse cytomegalovirus assessed as effect on virus-induced cytopathic effect
|
Murid herpesvirus 1
|
5.0
ug.mL-1
|
|
|
Antiviral activity against mouse cytomegalovirus by plaque-neutralization assay
|
Murid herpesvirus 1
|
13.8
ug.mL-1
|
|
|
Antiviral activity against human cytomegalovirus by plaque-neutralization assay
|
Human herpesvirus 5
|
3.4
ug.mL-1
|
|
|
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
7.6
ug.mL-1
|
|
|
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
4.9
ug.mL-1
|
|
|
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
9.1
ug.mL-1
|
|
|
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
1.5
ug.mL-1
|
|
|
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
0.54
ug.mL-1
|
|
|
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
9.4
ug.mL-1
|
|
|
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
6.0
ug.mL-1
|
|
|
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
6.2
ug.mL-1
|
|
|
Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation
|
Human herpesvirus 5 strain AD169
|
0.64
ug.mL-1
|
|
|
Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation
|
Human herpesvirus 5
|
1.9
ug.mL-1
|
|
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy
|
Homo sapiens
|
10.5
%
|
|
|
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity
|
Human herpesvirus 5 strain AD169
|
0.51
ug.mL-1
|
|
|
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity
|
Human herpesvirus 5
|
0.8
ug.mL-1
|
|
|
Antiviral activity against human cytomegalovirus
|
Human herpesvirus 5
|
30.0
%
|
|
|
Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 5 strain AD169
|
690.0
nM
|
|
|
Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 5 strain AD169
|
700.0
nM
|
|
|
Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 5
|
660.0
nM
|
|
|
Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
|
Maize chlorotic mottle virus
|
5.0
ug.mL-1
|
|
|
Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay
|
Human herpesvirus 3
|
26.7
ug.mL-1
|
|
|
Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days
|
Homo sapiens
|
100.0
ug.mL-1
|
|
|
Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days
|
Homo sapiens
|
840.0
ug.mL-1
|
|
|
Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
|
Human herpesvirus 1 strain KOS
|
20.0
nM
|
|
|
Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
|
Human herpesvirus 2 strain G
|
200.0
nM
|
|
|
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
Human herpesvirus 1 strain KOS
|
0.06
ug.mL-1
|
|
|
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
Human herpesvirus 2 strain G
|
0.06
ug.mL-1
|
|
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
Vaccinia virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
Vesicular stomatitis virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
Human herpesvirus 1 strain KOS
|
1.0
ug.mL-1
|
|
|
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
|
Human herpesvirus 3
|
590.0
nM
|
|
|
Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
Human herpesvirus 2 strain G
|
0.08
ug.mL-1
|
|
|
Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
Vaccinia virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
Vesicular stomatitis virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
Human herpesvirus 1 strain KOS
|
6.0
ug.mL-1
|
|
|
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
Human herpesvirus 1 strain KOS
|
0.08
ug.mL-1
|
|
|
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation
|
Human herpesvirus 5 strain AD169
|
1.4
ug.mL-1
|
|
|
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation
|
Cytomegalovirus
|
1.7
ug.mL-1
|
|
|
Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation
|
Human herpesvirus 3
|
1.0
ug.mL-1
|
|
|
Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation
|
Human herpesvirus 3
|
15.0
ug.mL-1
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
|
Human herpesvirus 1 strain KOS
|
30.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
|
Human herpesvirus 1 strain KOS
|
30.0
nM
|
|
|
Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay
|
Human herpesvirus 5
|
320.0
nM
|
|
|
Antiviral activity against 0.003 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay
|
Human herpesvirus 5 strain AD169
|
990.0
nM
|
|
|
Antiviral activity against 0.001 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay
|
Human herpesvirus 5 strain AD169
|
680.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus T3146 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay
|
Human herpesvirus 5
|
940.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus T3244 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay
|
Human herpesvirus 5
|
990.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus T3215 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay
|
Human herpesvirus 5
|
950.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus T3242 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay
|
Human herpesvirus 5
|
770.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus T3261 harboring Frt motif upstream of UL97 kinase infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay
|
Human herpesvirus 5
|
990.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus T3185 harboring Frt motif upstream of UL97 gene and expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay
|
Human herpesvirus 5
|
960.0
nM
|
|
|
Antiviral activity against human cytomegalovirus AD169 infected in human HFF assessed as inhibition of DNA synthesis after 72 hrs by qPCR
|
Human herpesvirus 5 strain AD169
|
98.0
%
|
|
|
Antiviral activity against 1 MOI human cytomegalovirus AD169 infected in human HFF assessed as virus yield reduction by yield reduction assay
|
Human herpesvirus 5 strain AD169
|
800.0
nM
|
|
|
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
Human herpesvirus 1 strain KOS
|
0.05
ug.mL-1
|
|
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
Human herpesvirus 2 strain G
|
0.07
ug.mL-1
|
|
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
Vaccinia virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
Vesicular stomatitis virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
Human herpesvirus 1 strain KOS
|
2.0
ug.mL-1
|
|
|
Antiviral activity against Feline coronavirus FIPV infected in cat CRFK cells assessed as protection against virus-induced cytopathogenicity after 2 days by MTS assay
|
Feline infectious peritonitis virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against Feline herpes virus infected in cat CRFK cells assessed as protection against virus-induced cytopathogenicity after 2 days by MTS assay
|
Felid herpesvirus 1
|
0.8
ug.mL-1
|
|
|
Antiviral activity against Feline herpesvirus 1 infected in cat CRFK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
Felid herpesvirus 1
|
100.0
ug.mL-1
|
|
|
Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
Feline coronavirus
|
1.7
ug.mL-1
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
Human herpesvirus 1 strain KOS
|
0.03
ug.mL-1
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
Human herpesvirus 2 strain G
|
0.03
ug.mL-1
|
|
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
Vaccinia virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
Vesicular stomatitis virus
|
100.0
ug.mL-1
|
|
|
Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
Human herpesvirus 1 strain KOS
|
58.0
ug.mL-1
|
|
|
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
|
Human herpesvirus 1 strain KOS
|
80.0
nM
|
|
|
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
|
Human herpesvirus 2 strain G
|
50.0
nM
|
|
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 1 strain KOS
|
10.0
nM
|
|
|
Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 1 strain KOS
|
100.0
nM
|
|
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 2 strain G
|
40.0
nM
|
|
|
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
|
Human herpesvirus 5 strain AD169
|
40.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
Human herpesvirus 1 strain KOS
|
30.0
nM
|
|
|
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
Human herpesvirus 1 strain KOS
|
800.0
nM
|
|
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay
|
Human herpesvirus 1 strain KOS
|
17.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 strain G assessed as reduction of virus induced cytopathicity by cell based assay
|
Human herpesvirus 2 strain G
|
23.0
nM
|
|
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay
|
Human herpesvirus 1 strain KOS
|
120.0
nM
|
|
|
Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
|
Human herpesvirus 1 strain KOS
|
30.0
nM
|
|
|
Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity
|
Human herpesvirus 2 strain G
|
27.0
nM
|
|
|
Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay
|
Human herpesvirus 5 strain Towne
|
140.0
nM
|
|
|
Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
10.0
nM
|
|
|
Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
|
Human herpesvirus 2 strain G
|
10.0
nM
|
|
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
Human herpesvirus 1 strain KOS
|
20.0
nM
|
|
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
|
Human herpesvirus 1
|
27.0
nM
|
|
|
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
|
Human herpesvirus 2 strain G
|
29.0
nM
|
|
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 2 strain G
|
13.0
nM
|
|
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 1 strain KOS
|
15.0
nM
|
|
|
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
Human herpesvirus 2 strain G
|
80.0
nM
|
|
|
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
Human herpesvirus 1 strain KOS
|
80.0
nM
|
|
|
Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation
|
Human herpesvirus 5
|
1.79
ug.mL-1
|
|
|
Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation
|
Human herpesvirus 5 strain AD169
|
2.68
ug.mL-1
|
|
|
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
Human herpesvirus 2 strain G
|
70.0
nM
|
|
|
Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
Human herpesvirus 1 strain KOS
|
90.0
nM
|
|
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
|
Human herpesvirus 2 strain G
|
900.0
nM
|
|
|
Antiviral activity against Feline Herpes virus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
|
Felid herpesvirus 1
|
900.0
nM
|
|
|
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation
|
Cytomegalovirus
|
380.0
nM
|
|
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
30.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
20.0
nM
|
|
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
500.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay
|
Herpes simplex virus (type 1 / strain F)
|
900.0
nM
|
|
|
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells
|
Cytomegalovirus
|
250.0
nM
|
|
|
Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells
|
Cytomegalovirus
|
400.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
|
Human herpesvirus 1 strain KOS
|
90.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
32.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity
|
Human herpesvirus 2 strain G
|
55.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 1 strain KOS
|
30.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 2 strain G
|
40.0
nM
|
|
|
Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 1 strain KOS
|
40.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
Human herpesvirus 1 strain KOS
|
100.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 1 strain KOS
|
20.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 2 strain G
|
20.0
nM
|
|
|
Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
Human herpesvirus 1 strain KOS
|
800.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection
|
Human herpesvirus 1 strain KOS
|
45.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection
|
Human herpesvirus 2 strain G
|
19.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection
|
Human herpesvirus 1 strain KOS
|
57.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection
|
Human herpesvirus 2 strain G
|
51.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method
|
Human alphaherpesvirus 1 strain KOS
|
10.0
nM
|
|
|
Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method
|
Human herpesvirus 2 strain G
|
10.0
nM
|
|
|
Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method
|
Human alphaherpesvirus 1 strain KOS
|
200.0
nM
|
|
|
Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
30.0
nM
|
|
|
Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity
|
Human herpesvirus 2 strain G
|
30.0
nM
|
|
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity
|
Human herpesvirus 1 strain KOS
|
500.0
nM
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)
|
Staphylococcus aureus subsp. aureus
|
7.88
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)
|
Escherichia coli
|
0.63
%
|
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
11.05
%
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
9.56
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600
|
Acinetobacter baumannii
|
17.44
%
|
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
0.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-0.42
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
3.23
%
|
|
|
Antiviral activity against HCMV TB40 infected in human HFF cells assessed as reduction in plaque formation treated with compound following viral infection and incubated for 8 to 10 days by crystal violet staining based assay
|
Human herpesvirus 5
|
720.0
nM
|
|
|
Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
|
Human alphaherpesvirus 1
|
40.0
nM
|
|
|
Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
|
Human alphaherpesvirus 2
|
580.0
nM
|
|
|
Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay
|
Murine cytomegalovirus (strain Smith)
|
960.0
nM
|
|
|
Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis
|
Human alphaherpesvirus 1
|
70.0
nM
|
|
|
Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis
|
Human alphaherpesvirus 2
|
400.0
nM
|
|
|
Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis
|
Human alphaherpesvirus 1
|
800.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis
|
Human alphaherpesvirus 1
|
70.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis
|
Human alphaherpesvirus 2
|
300.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 1 TK-KOS-ACV infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis
|
Human alphaherpesvirus 1
|
800.0
nM
|
|
|
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis
|
Human alphaherpesvirus 1
|
25.0
nM
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
6.335
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.14
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.14
%
|
|
|
Antiviral activity against Herpes simplex virus 1 infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis
|
Human herpesvirus 1
|
500.0
nM
|
|
|
Antiviral activity against Herpes simplex virus 2 infected in human HEL cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis
|
Human herpesvirus 2
|
200.0
nM
|
|
|
Antiviral activity against HCMV AD169 infected in human HFF cells assessed as reduction in virus-induced cytopathic effect incubated for 14 days by cell-titer glo assay
|
Human herpesvirus 5
|
900.0
nM
|
|
|
Antiviral activity against human cytomegalovirus expressing ADCREGFP infected in human HEL 299 cells assessed as reduction in viral replication by measuring GFP fluorescence incubated for 168 hrs by cell based assay
|
Human betaherpesvirus 5
|
930.0
nM
|
|
|
Antiviral activity against GFP-expressing HSV-1 assessed as reduction in viral growth by fluorescence assay
|
Human alphaherpesvirus 1
|
100.0
nM
|
|
